EDP317

N/A

Report date: 2022/05/31 17:48:11
NME

Base Information

Drug NameEDP317
Drug Alias NameMMKI - ACT BiotechACTB-1003EOC-317EDP-317
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptors antagonistsVascular endothelial growth factor receptor 2 inhibitors
TargetsFibroblast growth factor receptorsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBayer AGAct Biotech Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEddingpharm BvYiteng Pharmaceutical(Thaizhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsStomach NeoplasmsBiliary Tract Neoplasms +[4] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A